Skip to main content

Tranzyme Exclusively Licenses Trans-Lentiviral Vector Technology to Open Biosystems

NEW YORK, Nov. 14 (GenomeWeb News) - Open Biosystems has obtained an exclusive license to use Tranzyme Pharma's trans-lentiviral gene-expression technology, the company said today.

 

Under the agreement, Open Biosystems can develop and commercialize products based on the gene-expression technology. Open Biosystems will assume Tranzyme's Birmingham, Ala., operations and expand lentiviral-based product development and production.

 

Tranzyme will receive minimum annual payments and royalties on sales of products and services that depend on its technology, Open Biosystems said. The amount for the minimum payments was not disclosed.

 

Tranzyme's human-based trans-lentiviral gene expression technology can be used in neuroscience research, and Open Biosystems will provide proprietary research reagents and services based on lentiviral vectors.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.